Wikisage, the free encyclopedia of the second generation, is digital heritage
BIA 10-2474: Difference between revisions
Jump to navigation
Jump to search
(categ) |
mNo edit summary |
||
| Line 1: | Line 1: | ||
In January 2016 an experimental study on a fatty acid amide hydrolase inhibitor of the type FIH, led to death of a healthy volunteer. A case of cummulative toxicity. | In January 2016 an experimental study on a fatty acid amide hydrolase inhibitor of the type [[First in human|FIH]], led to death of a healthy volunteer. A case of cummulative toxicity. | ||
The molecule from Bial pharmaceutical company (Portela ca, Portugal) intended for enhancement of anandamide levels, its has a licking score (a formalin paw test) comparable to reference molecule [[gabapentine]] 300mg and 10 mg /Kg has a tail flick test maximum at 8 hour | The molecule from Bial pharmaceutical company (Portela ca, Portugal) intended for enhancement of anandamide levels, its has a licking score (a formalin paw test) comparable to reference molecule [[gabapentine]] 300mg and 10 mg /Kg has a tail flick test maximum at 8 hour | ||
Revision as of 00:44, 14 February 2017
In January 2016 an experimental study on a fatty acid amide hydrolase inhibitor of the type FIH, led to death of a healthy volunteer. A case of cummulative toxicity.
The molecule from Bial pharmaceutical company (Portela ca, Portugal) intended for enhancement of anandamide levels, its has a licking score (a formalin paw test) comparable to reference molecule gabapentine 300mg and 10 mg /Kg has a tail flick test maximum at 8 hour
